gene therapy, Regeneron Pharmaceuticals and deafness
Fuse Vectors has raised $5.2 million of funding as it moves closer to commercialising its innovative new approach to ...
Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...
Revolutionary gene therapy approaches show promise in treating various retinal conditions, potentially transforming treatment ...
Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...
An experimental trial of gene therapy has helped four toddlers - born with one of the most severe forms of childhood ...
The funding will accelerate the development of Fuse's technology platform and pipeline of novel gene therapies. With its ...
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...
Eleven children who were legally blind at birth all gained visual acuity after receiving MeiraGTx's investigational gene ...
In recent financial reports submitted to the Securities and Exchange Committee (SEC) in an 8-K filing, bluebird bio, Inc. (NASDAQ: BLUE), a leading biotech company, has provided an update on their ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback